July 7, 2015
A novel therapeutic for B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL).
This strategy promotes and protects the adaptive immune system, rather than abrogating its protective effects. Importantly, this approach will spare mature B cells that mediate the adaptive arm of the immune response. This is a particularly important feature of this therapeutic, since patients are highly susceptible to secondary infections during the steroid and chemotherapy phases of treatment.
B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is a common neoplasm in children and is an aggressive disease in adolescents and young adults. Overall survival for BCP-ALL has gradually improved from 10% in the 1960s to approximately 90% presently. Select subsets of patients, however, appear to have not benefitted from risk-adapted, intensified therapies. Because outcomes for high-risk leukemias appear to have plateaued with conventional therapy, the need for less toxic therapies has become greater. A present need remains for novel therapeutic approaches to help patients with BCP-ALL.
Researchers at the University of New Mexico and Sea Lane Biotechnologies have developed a novel therapeutic for B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). More specifically, this strategy promotes and protects the adaptive immune system, rather than abrogating its protective effects. Importantly, this approach will spare mature B cells that mediate the adaptive arm of the immune response. This is a particularly important feature of this therapeutic, since patients are highly susceptible to secondary infections during the steroid and chemotherapy phases of treatment.
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business communication (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
approximately 90% presently
technology description researchers
sea lane biotechnologies
anti-cd22 targeted therapy
adaptive immune system
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium